Cargando…

Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer

BACKGROUND: Excessive skeletal muscle loss during neoadjuvant concurrent chemoradiotherapy (NACRT) is significantly related to survival outcomes of oesophageal cancer. However, the conventional method for measuring skeletal muscle mass requires computed tomography (CT) images, and the calculation pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Han Gyul, Oh, Dongryul, Noh, Jae Myoung, Cho, Won Kyung, Sun, Jong‐Mu, Kim, Hong Kwan, Zo, Jae Ill, Shim, Young Mog, Kim, Kyunga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517349/
https://www.ncbi.nlm.nih.gov/pubmed/34145771
http://dx.doi.org/10.1002/jcsm.12747
_version_ 1784583997088595968
author Yoon, Han Gyul
Oh, Dongryul
Noh, Jae Myoung
Cho, Won Kyung
Sun, Jong‐Mu
Kim, Hong Kwan
Zo, Jae Ill
Shim, Young Mog
Kim, Kyunga
author_facet Yoon, Han Gyul
Oh, Dongryul
Noh, Jae Myoung
Cho, Won Kyung
Sun, Jong‐Mu
Kim, Hong Kwan
Zo, Jae Ill
Shim, Young Mog
Kim, Kyunga
author_sort Yoon, Han Gyul
collection PubMed
description BACKGROUND: Excessive skeletal muscle loss during neoadjuvant concurrent chemoradiotherapy (NACRT) is significantly related to survival outcomes of oesophageal cancer. However, the conventional method for measuring skeletal muscle mass requires computed tomography (CT) images, and the calculation process is labour‐intensive. In this study, we built machine‐learning models to predict excessive skeletal muscle loss, using only body mass index data and blood laboratory test results. METHODS: We randomly split the data of 232 male patients treated with NACRT for oesophageal cancer into the training (70%) and test (30%) sets for 1000 iterations. The naive random over sampling method was applied to each training set to adjust for class imbalance, and we used seven different machine‐learning algorithms to predict excessive skeletal muscle loss. We used five input variables, namely, relative change percentage in body mass index, albumin, prognostic nutritional index, neutrophil‐to‐lymphocyte ratio, and platelet‐to‐lymphocyte ratio over 50 days. According to our previous study results, which used the maximal χ (2) method, 10.0% decrease of skeletal muscle index over 50 days was determined as the cut‐off value to define the excessive skeletal muscle loss. RESULTS: The five input variables were significantly different between the excessive and the non‐excessive muscle loss group (all P < 0.001). None of the clinicopathologic variables differed significantly between the two groups. The ensemble model of logistic regression and support vector classifier showed the highest area under the curve value among all the other models [area under the curve = 0.808, 95% confidence interval (CI): 0.708–0.894]. The sensitivity and specificity of the ensemble model were 73.7% (95% CI: 52.6%–89.5%) and 74.5% (95% CI: 62.7%–86.3%), respectively. CONCLUSIONS: Machine learning model using the ensemble of logistic regression and support vector classifier most effectively predicted the excessive muscle loss following NACRT in patients with oesophageal cancer. This model can easily screen the patients with excessive muscle loss who need an active intervention or timely care following NACRT.
format Online
Article
Text
id pubmed-8517349
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85173492021-10-21 Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer Yoon, Han Gyul Oh, Dongryul Noh, Jae Myoung Cho, Won Kyung Sun, Jong‐Mu Kim, Hong Kwan Zo, Jae Ill Shim, Young Mog Kim, Kyunga J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Excessive skeletal muscle loss during neoadjuvant concurrent chemoradiotherapy (NACRT) is significantly related to survival outcomes of oesophageal cancer. However, the conventional method for measuring skeletal muscle mass requires computed tomography (CT) images, and the calculation process is labour‐intensive. In this study, we built machine‐learning models to predict excessive skeletal muscle loss, using only body mass index data and blood laboratory test results. METHODS: We randomly split the data of 232 male patients treated with NACRT for oesophageal cancer into the training (70%) and test (30%) sets for 1000 iterations. The naive random over sampling method was applied to each training set to adjust for class imbalance, and we used seven different machine‐learning algorithms to predict excessive skeletal muscle loss. We used five input variables, namely, relative change percentage in body mass index, albumin, prognostic nutritional index, neutrophil‐to‐lymphocyte ratio, and platelet‐to‐lymphocyte ratio over 50 days. According to our previous study results, which used the maximal χ (2) method, 10.0% decrease of skeletal muscle index over 50 days was determined as the cut‐off value to define the excessive skeletal muscle loss. RESULTS: The five input variables were significantly different between the excessive and the non‐excessive muscle loss group (all P < 0.001). None of the clinicopathologic variables differed significantly between the two groups. The ensemble model of logistic regression and support vector classifier showed the highest area under the curve value among all the other models [area under the curve = 0.808, 95% confidence interval (CI): 0.708–0.894]. The sensitivity and specificity of the ensemble model were 73.7% (95% CI: 52.6%–89.5%) and 74.5% (95% CI: 62.7%–86.3%), respectively. CONCLUSIONS: Machine learning model using the ensemble of logistic regression and support vector classifier most effectively predicted the excessive muscle loss following NACRT in patients with oesophageal cancer. This model can easily screen the patients with excessive muscle loss who need an active intervention or timely care following NACRT. John Wiley and Sons Inc. 2021-06-17 2021-10 /pmc/articles/PMC8517349/ /pubmed/34145771 http://dx.doi.org/10.1002/jcsm.12747 Text en © 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Yoon, Han Gyul
Oh, Dongryul
Noh, Jae Myoung
Cho, Won Kyung
Sun, Jong‐Mu
Kim, Hong Kwan
Zo, Jae Ill
Shim, Young Mog
Kim, Kyunga
Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
title Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
title_full Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
title_fullStr Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
title_full_unstemmed Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
title_short Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
title_sort machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517349/
https://www.ncbi.nlm.nih.gov/pubmed/34145771
http://dx.doi.org/10.1002/jcsm.12747
work_keys_str_mv AT yoonhangyul machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT ohdongryul machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT nohjaemyoung machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT chowonkyung machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT sunjongmu machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT kimhongkwan machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT zojaeill machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT shimyoungmog machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer
AT kimkyunga machinelearningmodelforpredictingexcessivemusclelossduringneoadjuvantchemoradiotherapyinoesophagealcancer